Very recently, the EMA has approved durvalumab for the treatment of patients with unresectable stage III NSCLC not progressing after chemoradiotherapy and whose tumors express PD-L1 on ≥1% of TC.
To improve treatment outcome in stage III NSCLC, it is necessary to obtain data on PD-L1 expression and CD8<sup>+</sup> TIL counts following CCRT and their relationship to treatment outcome.
Here, we discuss the clinical and translational implications of integrating PD-1/PD-L1 inhibitors in the management of patients with unresectable stage III NSCLC.<i></i>.
The PD-L1 inhibitor durvalumab increases progression-free survival and objective response rate in patients with inoperable and locally advanced stage III non-small cell lung cancer, according to interim results of a phase III trial.